TY - JOUR
T1 - Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region
AU - Castellsagué, Xavier
AU - Ault, Kevin A.
AU - Bosch, F. Xavier
AU - Brown, Darron
AU - Cuzick, Jack
AU - Ferris, Daron G.
AU - Joura, Elmar A.
AU - Garland, Suzanne M.
AU - Giuliano, Anna R.
AU - Hernandez-Avila, Mauricio
AU - Huh, Warner
AU - Iversen, Ole Erik
AU - Kjaer, Susanne K.
AU - Luna, Joaquin
AU - Monsonego, Joseph
AU - Muñoz, Nubia
AU - Myers, Evan
AU - Paavonen, Jorma
AU - Pitisuttihum, Punnee
AU - Steben, Marc
AU - Wheeler, Cosette M.
AU - Perez, Gonzalo
AU - Saah, Alfred
AU - Luxembourg, Alain
AU - Sings, Heather L.
AU - Velicer, Christine
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region. Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3. Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3.
AB - Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region. Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3. Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3.
KW - Adenocarcinoma in situ
KW - Cervical cancer
KW - Cervical intraepithelial neoplasia
KW - Human papillomavirus
UR - http://www.scopus.com/inward/record.url?scp=84961675401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961675401&partnerID=8YFLogxK
U2 - 10.1016/j.pvr.2016.03.002
DO - 10.1016/j.pvr.2016.03.002
M3 - Article
C2 - 29074187
AN - SCOPUS:84961675401
VL - 2
SP - 61
EP - 69
JO - Papillomavirus Research
JF - Papillomavirus Research
SN - 2405-8521
ER -